0001209191-20-025937.txt : 20200428
0001209191-20-025937.hdr.sgml : 20200428
20200428162337
ACCESSION NUMBER: 0001209191-20-025937
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200424
FILED AS OF DATE: 20200428
DATE AS OF CHANGE: 20200428
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lee Yuchun
CENTRAL INDEX KEY: 0001334365
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 20825366
MAIL ADDRESS:
STREET 1: 170 TRACER LA.
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-04-24
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001334365
Lee Yuchun
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
0
0
0
Common Stock
2020-04-24
4
M
0
2000
57.27
A
3875
D
Common Stock
2020-04-24
4
S
0
890
267.23
D
2985
D
Common Stock
2020-04-24
4
S
0
590
268.31
D
2395
D
Common Stock
2020-04-24
4
S
0
400
269.28
D
1995
D
Common Stock
2020-04-24
4
S
0
120
270.30
D
1875
D
Common Stock
2020-04-27
4
M
0
2000
57.27
A
3875
D
Common Stock
2020-04-27
4
S
0
193
268.40
D
3682
D
Common Stock
2020-04-27
4
S
0
394
270.37
D
3288
D
Common Stock
2020-04-27
4
S
0
1113
271.56
D
2175
D
Common Stock
2020-04-27
4
S
0
200
272.51
D
1975
D
Common Stock
2020-04-27
4
S
0
100
273.44
D
1875
D
Stock Option (Right to Buy)
57.27
2020-04-24
4
M
0
2000
0.00
D
2022-09-13
Common Stock
2000
3125
D
Stock Option (Right to Buy)
57.27
2020-04-27
4
M
0
2000
0.00
D
2022-09-13
Common Stock
2000
1125
D
Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $267.23 (range $266.72 to $267.71).
Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $268.31 (range $267.94 to $268.77).
Open market sales reported on this line occurred at a weighted average price of $269.28 (range $269.00 to $269.64).
Open market sales reported on this line occurred at a weighted average price of $270.30 (range $270.05 to $270.33).
Open market sales reported on this line occurred at a weighted average price of $268.40 (range $268.05 to $268.77).
Open market sales reported on this line occurred at a weighted average price of $270.37 (range $270.08 to $270.78).
Open market sales reported on this line occurred at a weighted average price of $271.56 (range $271.12 to $272.00).
Open market sales reported on this line occurred at a weighted average price of $272.51 (range $272.31 to $272.71).
Fully vested.
/s/ Omar White, Attorney-in-Fact
2020-04-28